Theoretical Error Rates of Qualitative UDS Tests for Stimulants Neal Oden, PhD, Paul VanVeldhuisen, PhD, NIDA Data and Statistics Center 2, The EMMES Corporation.

Slides:



Advertisements
Similar presentations
Assumptions and Conditions
Advertisements

Presenters: Promoting Regulatory Excellence Use of Substance Abuse Testing in Licensure Actions Donna R. Smith, PhD FirstLab, Inc.
Procedural Learning among HIV+ and HIV- individuals with Substance Dependence R. Gonzalez, J. Jacobus, J.W. Rodriguez, E.H. Fakhoury, E.M. Martin.
Background: The low retention rates among African Americans in substance abuse treatment (Milligan et al., 2004) combined with the limited number of treatments.
Cognitive Walkthrough More evaluation without users.
1 Copyright © 2005 Brooks/Cole, a division of Thomson Learning, Inc. Analysis of Categorical Data Tests for Homogeneity.
Section 17: Treatment Planning. 2 Icebreaker How do you define treatment planning?
Sample size optimization in BA and BE trials using a Bayesian decision theoretic framework Paul Meyvisch – An Vandebosch BAYES London 13 June 2014.
Dennis M. Donovan, Ph.D., Michael P. Bogenschutz, M.D., Harold Perl, Ph.D., Alyssa Forcehimes, Ph.D., Bryon Adinoff, M.D., Raul Mandler, M.D., Neal Oden,
CDRH Review Practice for Over-the-Counter in Vitro Diagnostic Tests
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2010.
Drug Medi-Cal Waiver Evaluation Planning Darren Urada, Ph.D. UCLA Integrated Substance Abuse Programs January 5, 2015 The author’s views and recommendations.
BS704 Class 7 Hypothesis Testing Procedures
Today Today: Finish Chapter 9, start Chapter 10 Sections from Chapter 9: 9.1, 9.4, 9.5, 9.10 (know just class notes for these sections) Recommended Questions:
Cotinine is an Unreliable Biomarker for Systemic Exposure in Spit Tobacco Users Jon O. Ebbert, MD, MSc Lowell C. Dale, MD Liza Nirelli Darrell Schroeder,
Results of a Brief Intervention for Reducing Alcohol Use among HIV Positive Women in Cape Town, South Africa This study was funded by NICHD grant number.
Practicalities of Conducting Biological Assessments for Drug Use Kenzie L. Preston, Ph.D. Chief, Clinical Pharmacology and Therapeutics Research Branch.
Enzyme-linked immunosorbent assay Microtiter well EEEEE Specimen 2nd antibody E Substrate SP.
Discussion Gitanjali Batmanabane MD PhD. Do you look like this?
Overview of Statistical Hypothesis Testing: The z-Test
A secondary analysis of a study of 152 subjects aged seeking treatment for opioid dependence were randomized to 2 week detoxification with buprenorphine/naloxone.
Audrey J. Brooks, PhD University of Arizona CA-AZ node.
Frequency and type of adverse events associated with treating women with trauma in community substance abuse treatment programs T. KIlleen 1, C. Brown.
Statistical Fundamentals: Using Microsoft Excel for Univariate and Bivariate Analysis Alfred P. Rovai Hypothesis Testing PowerPoint Prepared by Alfred.
Statistics for Health Care Biostatistics. Phases of a Full Clinical Trial Phase I – the trial takes place after the development of a therapy and is designed.
/CITAC / 1 Identification, Measurement and Decision in Analytical Chemistry Steve Ellison LGC, England.
Systematic Reviews.
Using self report to gather information about drug use can be reasonably reliable and valid in certain situations, especially where there are no contingencies.
Effect of Depression on Smoking Cessation Outcomes Sonne SC 1, Nunes EV 2, Jiang H 2, Gan W 2, Tyson C 1, Reid MS 3 1 Medical University of South Carolina,
Obtaining housing associated with achieving abstinence after detoxification in adults with addiction Tae Woo Park, Christine Maynié-François, Richard Saitz.
Blattler et al (2002). Aim To investigate whether supplying heroin on a medical programme, combined with therapy, would reduce cocaine use among participants,
Study Design for a Randomized Controlled Trial of Osmotic-Release Methylphenidate (OROS-MPH) Osmotic-Release Methylphenidate (OROS-MPH) for Attention Deficit.
Criminal Justice Referral and Incentives in Outpatient Substance Abuse Treatment Anthony DeFulio 1, Paul Nuzzo 2, & Maxine Stitzer 1 1 – Johns Hopkins.
CCTN September 6 th, Recent Scientific Publications from the Clinical Trials Network David Liu, M.D. (CTN-0029) Harold Perl, Ph.D. (CTN-0015) Paul.
1 SCREENING. 2 Why screen? Who wants to screen? n Doctors n Labs n Hospitals n Drug companies n Public n Who doesn’t ?
PAMI Promoting Awareness of Motivational Incentives: Focus on Founding Principles and an Implementation Checklist Donald A Calsyn, Ph.D. Pacific Northwest.
Monitoring the Progress of Clinical Trials in a Network Setting: Experience from the National Drug Abuse Treatment Clinical Trials Network P. VanVeldhuisen.
Participants were recruited from 6 drug free, psychosocial treatment (PT) and 5 methadone maintenance (MM) programs (N = 628) participating in a NIDA Clinical.
Abstinence Incentives for Methadone Maintained Stimulant Users: Outcomes for Those Testing Stimulant Positive vs Negative at Study Intake Maxine L. Stitzer.
How to find a paper Looking for a known paper: –Field search: title, author, journal, institution, textwords, year (each has field tags) Find a paper to.
The COMBINE Study: Design and Methodology Stephanie S. O’Malley, Ph.D. for The COMBINE Study Research Group JAMA Vol. 295, , 2006 (May 3 rd.
Chapter 7 Probability and Samples: The Distribution of Sample Means
· Lecture 31 & 32 : Scope of clinical biochemistry ط Uses of clinical biochemistry tests ط Diagnosis, Prognosis, Screening, Monitoring ط Reporting results.
Objective: To utilize preclinical and phase I PK/PD data from a new quinolone (Q) and relevant public domain data to develop an exposure-response model.
Methamphetamine: User Characteristics and Treatment Response Alice Huber, Ph.D. Steven Shoptaw, Ph.D. Richard A. Rawson, Ph.D. Paul Brethen, M.A. Walter.
Abstinence Incentive Effects in Psychosocial Counseling Patients Testing Stimulant Positive vs Negative at Treatment Entry Maxine L. Stitzer Johns Hopkins.
Table 1. Prediction model for maximum daily dose of buprenorphine-naloxone in a 12-week treatment condition Baseline Predictors Maximum Daily Dose Standardized.
SMOKING in ADOLESCENTS with PSYCHIATRIC or ADDICTIVE DISORDERS.
Relational Discord at Conclusion of Treatment Predicts Future Substance Use for Partnered Patients Wayne H. Denton, MD, PhD; Paul A. Nakonezny, PhD; Bryon.
Research Report. Introduction Introduce the research problem Introduce the research problem Why is the study important and to whom Why is the study important.
Lipids Standardization and DAGs Enrique Schisterman, PhD Epidemiology Branch – DESPR – NICHD 1.
Verification of qualitative methods
Organization of statistical research. The role of Biostatisticians Biostatisticians play essential roles in designing studies, analyzing data and.
Jennifer R. Havens, PhD, MPH Associate Professor
TM Substance Use Transitions from Initial Use to Regular Use to Discontinuance Ralph S. Caraballo, Ph.D., MPH Office on Smoking and Health, CDC, Atlanta.
Unit 4 Seminar Contd… (we shall pick up where we left off last seminar to discuss some key concepts)
What the National Institute on Drug Abuse’s Clinical Trials Network Can Do for You? Major Findings from Medication Trials and Implications for Community-Based.
A Pharmacokinetic Drug Interaction Study of Drug-72 and Drug-12 Department of Mathematic & Statistics York University Yufeng Lin Xiaofeng Zhou.
Randomized Controlled CTN Trial of OROS-MPH + CBT in Adolescents with ADHD and Substance Use Disorders Paula Riggs, M.D., Theresa Winhusen, PhD., Jeff.
Background  Substance abusers are at risk for HIV and other STIs.  Anal intercourse (AI) is riskier than vaginal intercourse.  Studies of AI have focused.
NAAT identified chlamydial infections: Enhanced sensitivity, reduced transmissibility? Presenter: Maria Villarroel, MA Authors: Maria A. Villarroel, MA.
Pharmacokinetics (PK) and Pharmacodynamics (PD) of Rivaroxaban: A Comparison of Once- and Twice-daily Dosing in Patients Undergoing Total Hip Replacement.
Medication Adherence and Substance Abuse Predict 18-Month Recidivism among Mental Health Jail Diversion Program Clients Elizabeth N. Burris 1, Evan M.
Overview of the cannabis use in Europe Paul Griffiths, Reitox academy, Berlin, 29th March 2007.
PURPOSE BACKGROUND RESULTS STUDY DESIGN & METHODS HIV Risk Behaviors Among Male Prisoners Participating in a Randomized Clinical Trial of Methadone Maintenance.
“Reading and commenting papers” (Scientific English) Alexis Descatha INSERM, UMS UVSQ- Unité de pathologie professionnelle, Garches.
An Alternative to Data Imputation in Analgesic Clinical Trials David Petullo, Thomas Permutt, Feng Li Division of Biometrics II, Office of Biostatistics.
L.S. Remy1, G. Woody2, K. Lynch2, K. M. Kampman2
Strategies to incorporate pharmacoeconomics into pharmacotherapy
Isabel C. Scarinci, PhD, MPH James Kendrick, MD Edward Partridge, MD
Presentation transcript:

Theoretical Error Rates of Qualitative UDS Tests for Stimulants Neal Oden, PhD, Paul VanVeldhuisen, PhD, NIDA Data and Statistics Center 2, The EMMES Corporation Second SimulationFirst Simulation Clinical trials in cocaine abuse and addiction often use a urine drug screen (UDS) as part of the primary outcome. Operationally, a popular approach is to consider a positive qualitative UDS (BE concentration > 300 ng/ml) on day 0 as indicating that there must have been drug use at least once during days -1 to -3, while a negative qualitative UDS is interpreted as indicating that there cannot have been drug use on those days. Call this the X-test. How unrealistic are the assumptions of the X-test? There are at least two potential sources of error. The first, which involves the laboratory analysis, concerns the accuracy with which the UDS determines BE concentration. The second, which is more concerned with human behavior, hinges on whether a high BE concentration day 0 is reliably associated with drug-taking behavior on days -3 to -1. We ignore the first source, and attempt to determine theoretical error rates associated with the second source. Li et al. express BE concentration in urine as a function of initial dose and time since dose. An implication is that, because BE clears so quickly, test outcomes depend mostly on time since most recent dose. We use Li’s expression in conjunction with assumptions about normality and behavior of participants in addiction trials to derive theoretical curves showing sensitivity, specificity, positive predictive value, and negative predictive value of the X-test as a function of probability of daily drug use. Under these assumptions, the probabilities of false negative and false positive are not likely to be more than Abstract Background Urine Drug Screen (UDS) results are often outcomes of clinical trials for cocaine use Operationally, one way to use UDS is to: –Measure urinary concentration of benzoylecgonine (BE), a cocaine metabolite –Consider urine positive if BE concentration exceeds 300 ng/ml –Take positive urine on day 0 to indicate drug use some time between day -3 and day -1, while negative urine indicates no use on those days Call this “the X test” How accurate is the X test? Two sub-questions: –How accurately can a lab test determine whether BE concentration exceeds 300? –What does BE > 300 tell us about past cocaine use? We use simulation to begin to answer the second question Research supported by the National Institute on Drug Abuse, National Drug Abuse Treatment Clinical Trials Network, National Institutes of Health, through Contract No. HHSN C. Acknowledgement Source: Li SH, Chiang N, Tai B, Marschke CK, Hawks RL: NIDA Research Monograph 175, 1997 One-compartment Pharmacokinetic Model for IV Cocaine Disposition Summary of Simulation Conclusions In a population of IV cocaine users who use not more than once a day: – Probability of positive urine depends mostly on time since most recent use Log-normal approximation is fairly accurate – If probability of drug-taking is about 0.3 to 0.4 per day, X-test accuracy is as follows: – sensitivity – specificity> 0.95 – positive predictive value~1 – negative predictive value Time since most recent use: – If urine positive, probably yesterday – If urine negative, probably 3-4 days ago